Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
Go back to Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1223.46 -8.48 (0.69%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1231.94 | 52 Week High | $88.16 | |||
| Open | $1230.65 | 52 Week Low | $67.88 | |||
| Day High | $1238.00 | P/E | 283.21 | |||
| Day Low | $1210.01 | EPS | $4.32 | |||
| Volume | 748,433 | |||||
